RCS - Roquefort Theraptcs. - ROQ Presents Study Results at the ESGCT Conference

Roquefort TherapeuticsAnnouncement

11/10/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221011:nRSK4070Ca&default-theme=true

RNS Number : 4070C  Roquefort Therapeutics PLC  11 October 2022

11 October 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Roquefort Therapeutics Presents Study Results at the ESGCT Conference

Abstract accepted at leading cell and gene therapy conference

 

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech
company focused on developing first in class medicines in the high value and
high growth oncology market, is pleased to announce that the results of its
anti-cancer RNA pre-clinical study will be presented later today at the 29(th)
European Society of Gene & Cell Therapy ("ESGCT") in Edinburgh. The
results demonstrate for the first time that a splice switching RNA medicine
can impair Midkine action by inducing a change in the Midkine mRNA, that not
only reduces full length Midkine but also generates a non-functional shortened
Midkine. Production of truncated Midkine has been shown to reduce the size of
cancers in vivo and underpins the potential for anti-Midkine RNA medicines to
treat cancer in patients.

The co-authors are Drs Cale and Aung-Htut and Professor Wilton from Murdoch
University, and Dr Graham Robertson, Vice President of Drug Discovery,
Roquefort Therapeutics.  The poster, number P482, is embargoed until the
presentation at the conference but will then be available at the Roquefort
Therapeutics website.

Further details of the event may be found on the ESGCT website:

https://www.esgctcongress.com/poster-list
(https://www.esgctcongress.com/poster-list)

Ajan Reginald, Chief Executive Officer, commented:

"Congratulations to the team on reaching this milestone and reporting the
results at the ESGCT conference, Europe's leading cell and gene therapy
scientific meeting.  RNA oligonucleotide-based medicines are an innovative
new approach to treat the cancers that are resistant to existing drugs. At
Roquefort Therapeutics, we are developing a portfolio of anti-cancer medicines
to block some of the most novel cancer targets like Midkine and STAT-6. We
have shown blocking these factors kills cancer cells.

For the first time, an RNA medicine has been shown to switch-off functional
Midkine production in cancer cells. This proof-of-concept study highlights the
potential for a new class of medicines blocking Midkine production to target
some of the most difficult to treat cancers."

-Ends-

Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman) / Ajan Reginald (CEO)  +44 (0)20 3918 8633

 Hybridan LLP (Joint Broker)

 Claire Louise Noyce                            +44 (0)203 764 2341

 Optiva Securities Limited (Joint Broker)
 Christian Dennis                               +44 (0)20 3411 1881

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale       +44 (0)20 7466 5000

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech
company developing first in class drugs in the high value and high growth
oncology segment prior to partnering or selling to big pharma.

 

Since listing in March 2021, Roquefort Therapeutics has successfully acquired
Lyramid Pty Limited, a leader in the development of medicines for a new
therapeutic target, Midkine (a human growth factor associated with cancer
progression), and most recently acquired Oncogeni Ltd, founded by Nobel
Laureate Professor Sir Martin Evans, which has developed two families of
innovative cell and RNA oncology medicines.

 

Roquefort Therapeutics' portfolio consists of four fully funded, novel
patent-protected pre-clinical anti-cancer medicines.  The highly
complementary profile of four best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    MK cell therapy with direct and NK-mediated anti-cancer action; and

·    siRNA targeting novel STAT-6 target in solid tumours showing
significant in vivo efficacy.

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMMBPTMTIBBLT